With Sarah Cannon Research Institute, AstraZeneca Genomically Profiling Patients for Drug Trials | GenomeWeb

This article has been updated with additional information from Sarah Cannon Research Institute.Originally published July 2.

Extending an existing drug development research pact, AstraZeneca and Sarah Cannon Research Institute this week said they would work together to identify patients for drug development trials based on their genetic profiles.

For this collaboration, AstraZeneca will make its portfolio of oncology small molecule drugs available to SCRI. The drug developer has formed a team to partner with SCRI on the project.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.